Krystal Biotech
KRYS
283 hedge funds and large institutions have $5.15B invested in Krystal Biotech in 2024 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 107 increasing their positions, 89 reducing their positions, and 15 closing their positions.
260% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 15
34% more call options, than puts
Call options by funds: $89.7M | Put options by funds: $67.2M
20% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 89
16% more funds holding
Funds holding: 245 → 283 (+38)
2% less capital invested
Capital invested by funds: $5.24B → $5.15B (-$91.1M)
1.46% less ownership
Funds ownership: 99.89% → 98.44% (-1.5%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$44.9M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$36.5M |
| 3 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$23.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$23.1M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$40.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$31.2M |
| 3 |
Goldman Sachs
New York
|
-$23.3M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$21.6M |
| 5 |
Jennison Associates
New York
|
-$21.3M |
KRYS Hedge Fund Activity: Q3 2024 in Review
283 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2024, worth a combined $5.15B — down 1.7% from $5.24B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new KRYS positions and 15 closed out — a net gain of 39 holders — while 107 added to existing stakes and 89 trimmed.
The largest buyer was Norges Bank, adding an estimated $44.9M. The largest seller was Redmile Group, cutting an estimated $40.7M.
- 283 institutional investors held Krystal Biotech (KRYS) as of Q3 2024, up from 245 in Q2 2024.
- Funds reported $5.15B of Krystal Biotech stock for Q3 2024, down 1.7% quarter-over-quarter.
- 54 funds opened new Krystal Biotech positions in Q3 2024 and 15 closed out, a net change of +39 holders.
- The largest Krystal Biotech buyer in Q3 2024 was Norges Bank, an estimated $44.9M added.
- The largest Krystal Biotech seller in Q3 2024 was Redmile Group, an estimated $40.7M sold.
Based on aggregated 13F filings for Q3 2024.